We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+5.01%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.83B
AUM Growth
+$68.6M
(+3.9%)
Cap. Flow
+$3.9M
Cap. Flow
% of AUM
0.21%
Top 10 Holdings %
Top 10 Hldgs %
57.7%
Holding
56
New
18
Increased
13
Reduced
11
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$139M |
| 2 |
Biogen
BIIB
|
+$125M |
| 3 |
Edwards Lifesciences
EW
|
+$69.3M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$63.8M |
| 5 |
AET
Aetna Inc
AET
|
+$57.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$106M |
| 2 |
DexCom
DXCM
|
+$93.9M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
+$92.7M |
| 4 |
Zimmer Biomet
ZBH
|
+$58.3M |
| 5 |
Quest Diagnostics
DGX
|
+$53.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.22% |
| 2 | Financials | 6.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Edwards Lifesciences
EW
$50B
| $150M | 8.16% |
4,500,000
+2,025,000
| +82% | +$69.3M |
|
2
Labcorp
LH
$25.9B
| $143M | 7.82% |
1,280,400
+174,600
| +16% | +$18.8M |
|
|
HOLX
3
DELISTED
Hologic
HOLX
| $138M | 7.55% |
+4,000,000
| New | +$139M |
|
|
AET
4
DELISTED
Aetna Inc
AET
| $122M | 6.66% |
1,000,000
+500,000
| +100% | +$57.4M |
|
|
5
Zimmer Biomet
ZBH
$18.4B
| $120M | 6.57% |
1,030,000
-515,000
| -33% | -$58.3M |
|
|
6
Biogen
BIIB
$30.7B
| $115M | 6.26% |
+475,000
| New | +$125M |
|
|
7
Quest Diagnostics
DGX
$25.9B
| $93.6M | 5.11% |
1,150,000
-700,000
| -38% | -$53.3M |
|
|
AKRX
8
DELISTED
Akorn Inc
AKRX
| $59.8M | 3.26% |
2,100,000
-1,075,000
| -34% | -$29.8M |
|
|
9
BioMarin Pharmaceuticals
BMRN
$11.7B
| $58.4M | 3.18% |
+750,000
| New | +$63.8M |
|
10
CALL
Merck
MRK
$321B
| $57.6M | 3.14% |
+1,048,000
| New | +$55.8M |
|
11
Encompass Health
EHC
$11B
| $56.3M | 3.07% |
1,822,650
+439,950
| +32% | +$13.8M |
|
|
QGENF
12
DELISTED
QIAGEN NV
QGENF
| $54.5M | 2.97% |
+2,500,000
| New | +$54.5M |
|
|
WBA
13
DELISTED
Walgreens Boots Alliance
WBA
| $41.4M | 2.26% |
+496,680
| New | +$40.1M |
|
|
HRC
14
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $41.1M | 2.24% |
+815,603
| New | +$41.1M |
|
15
Humana
HUM
$44B
| $38.7M | 2.11% |
214,920
+14,920
| +7% | +$2.65M |
|
16
Acadia Healthcare
ACHC
$2.62B
| $37.9M | 2.07% |
+684,220
| New | +$40M |
|
|
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
| $36.4M | 1.98% |
2,650,000
+650,000
| +33% | +$9.5M |
|
18
Thermo Fisher Scientific
TMO
$214B
| $34.5M | 1.88% |
233,245
-141,755
| -38% | -$20.9M |
|
19
Icon
ICLR
$12.8B
| $33.3M | 1.81% |
475,000
+73,600
| +18% | +$5.05M |
|
20
Universal Health Services
UHS
$9.88B
| $32.7M | 1.78% |
243,490
-381,510
| -61% | -$50.3M |
|
|
21
DexCom
DXCM
$28.8B
| $31.4M | 1.71% |
1,584,120
-5,515,880
| -78% | -$93.9M |
|
22
Revvity
RVTY
$12.7B
| $30.5M | 1.67% |
+582,500
| New | +$30.6M |
|
|
CVRS
23
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $28.6M | 1.56% |
19,981,655
| – | – |
|
|
EVHC
24
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $26.7M | 1.46% |
+351,421
| New | +$25M |
|
25
CVS Health
CVS
$134B
| $22.8M | 1.24% |
+237,830
| New | +$23.7M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2016 Portfolio in Review
As of Q2 2016, HealthCor Management held 56 positions worth $1.83B, up 3.9% from $1.76B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
HealthCor Management's Q2 2016 filing shows 18 new, 13 increased, 11 reduced and 13 closed positions. Its largest new stake was Hologic: 4,000,000 shares worth $138M. The largest sale was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $106M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials.
- HealthCor Management's largest Q2 2016 buy was Hologic: 4,000,000 shares worth $138M.
- HealthCor Management added most to Edwards Lifesciences in Q2 2016, an estimated $69.3M increase.
- HealthCor Management's biggest Q2 2016 reduction was DexCom, cutting an estimated $93.9M.
- HealthCor Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q2 2016, selling an estimated $106M.
- HealthCor Management's ten largest holdings make up 58% of its $1.83B portfolio in Q2 2016.
- HealthCor Management opened 18 new positions and closed 13 in Q2 2016.
- HealthCor Management's portfolio value rose 3.9% quarter-over-quarter to $1.83B.
Based on HealthCor Management's 13F filing for Q2 2016, filed 15 Aug 2016.